X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1668) 1668
Book Review (481) 481
Newspaper Article (189) 189
Publication (156) 156
Newsletter (58) 58
Book Chapter (19) 19
Trade Publication Article (9) 9
Magazine Article (6) 6
Book / eBook (3) 3
Conference Proceeding (3) 3
Dissertation (3) 3
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sarcopenia (1740) 1740
index medicus (1226) 1226
humans (1019) 1019
aged (644) 644
male (578) 578
female (527) 527
aging (395) 395
middle aged (353) 353
muscles (352) 352
musculoskeletal system (335) 335
geriatrics & gerontology (331) 331
skeletal-muscle (329) 329
exercise (292) 292
body composition (290) 290
aged, 80 and over (267) 267
animals (263) 263
body-composition (261) 261
research (261) 261
cancer (258) 258
oncology (235) 235
health aspects (226) 226
care and treatment (224) 224
analysis (222) 222
skeletal muscle (222) 222
mortality (218) 218
obesity (218) 218
medicine & public health (216) 216
older people (210) 210
cachexia (208) 208
risk factors (204) 204
physiological aspects (197) 197
adult (195) 195
age (195) 195
chemotherapy (188) 188
body mass index (187) 187
nutrition & dietetics (187) 187
nutrition (180) 180
endocrinology & metabolism (178) 178
older-adults (178) 178
frailty (177) 177
sarcopenia - physiopathology (174) 174
prognosis (168) 168
muscle strength (159) 159
muscle, skeletal - drug effects (158) 158
muscle, skeletal - metabolism (158) 158
osteoporosis (156) 156
proteins (155) 155
muscle, skeletal - pathology (152) 152
internal medicine (144) 144
prevalence (144) 144
aging - physiology (141) 141
sarcopenia - drug therapy (140) 140
strength (135) 135
studies (135) 135
medical research (134) 134
metabolism (132) 132
medicine (131) 131
patients (131) 131
dietary supplements (130) 130
muscle mass (125) 125
women (122) 122
medicine, general & internal (121) 121
article (119) 119
geriatrics (119) 119
sarcopenia - diagnosis (118) 118
inflammation (117) 117
mice (117) 117
diabetes (116) 116
clinical trials (114) 114
survival (113) 113
sarcopenia - etiology (111) 111
geriatrics/gerontology (110) 110
atrophy (108) 108
treatment outcome (108) 108
malnutrition (107) 107
muscle (107) 107
cell biology (106) 106
physiology (106) 106
physical fitness (104) 104
adults (103) 103
drug therapy (101) 101
medicine, experimental (101) 101
oxidative stress (100) 100
quality of life (100) 100
sarcopenia - therapy (100) 100
muscle, skeletal - physiopathology (98) 98
retrospective studies (98) 98
sarcopenia - complications (98) 98
gerontology (97) 97
sarcopenia - epidemiology (96) 96
surgery (96) 96
weight-loss (94) 94
mass (93) 93
elderly (92) 92
muscle, skeletal - physiology (92) 92
diet (91) 91
review (91) 91
diagnosis (90) 90
sarcopenia - metabolism (90) 90
health (88) 88
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1913) 1913
Japanese (10) 10
French (9) 9
German (8) 8
Spanish (5) 5
Italian (2) 2
Russian (2) 2
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Nutrition, ISSN 0261-5614, 2015, Volume 35, Issue 3, pp. 724 - 730
Summary Background & aims Profound weight loss and malnutrition subsequent to severe dysphagia and cancer cachexia are cardinal symptoms in oesophageal cancer... 
Gastroenterology and Hepatology | Sarcopenic obesity | Sarcopenia | Oesophageal cancer | Chemotherapy | Body composition | SURGERY | WEIGHT-LOSS | DETERMINANT | RENAL-CELL CARCINOMA | COMPUTED-TOMOGRAPHY | SKELETAL-MUSCLE | NUTRITION & DIETETICS | COLORECTAL-CANCER | ATTENUATION | BODY-MASS INDEX | ADIPOSE-TISSUE VOLUMES | Chemoradiotherapy - adverse effects | Overweight - complications | Cachexia - chemically induced | Humans | Middle Aged | Sarcopenia - complications | Male | Antineoplastic Agents - therapeutic use | Esophageal Neoplasms - radiotherapy | Antineoplastic Agents - administration & dosage | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Esophageal Neoplasms - complications | Carcinoma - complications | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Carcinoma - pathology | Adenocarcinoma - radiotherapy | Body Mass Index | Carcinoma - drug therapy | Obesity - complications | Risk Factors | Carcinoma - radiotherapy | Academic Medical Centers | Sweden - epidemiology | Adenocarcinoma - drug therapy | Adenocarcinoma - complications | Cachexia - epidemiology | Pilot Projects | Neoadjuvant Therapy - adverse effects | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Obesity | Cancer patients | Adjuvant treatment | Health aspects | Risk factors | Esophageal cancer | Cancer | Index Medicus
Journal Article
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 2014, Volume 41, Issue 3, pp. 333 - 338
Journal Article
Journal Article
European Radiology, ISSN 0938-7994, 5/2014, Volume 24, Issue 5, pp. 998 - 1005
Journal Article
Bone, ISSN 8756-3282, 12/2017, Volume 105, pp. 75 - 86
Adiponectin regulates various metabolic processes including glucose flux, lipid breakdown and insulin response. We recently reported that adiponectin receptor1... 
Sarcopenia | PGC1α | Anti-resorptive | Sclerostin | Osteopenia | Osteoanabolic | Adiponectin receptor-1 | Adiponectin | BONE-MINERAL DENSITY | MUSCLE | RECEPTOR | ADIPOR1 | OSTEOPOROSIS | MASS | ENDOCRINOLOGY & METABOLISM | PARATHYROID-HORMONE | FRACTURES | DIFFERENTIATION | PGCl alpha | POSTMENOPAUSAL WOMEN | Sarcopenia - complications | Oxidative Phosphorylation - drug effects | Bone Morphogenetic Proteins - metabolism | Body Composition - drug effects | Adenylate Kinase - metabolism | Cell Respiration - drug effects | Adiponectin - therapeutic use | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism | Female | Sarcopenia - drug therapy | Adiponectin - pharmacology | Glucose Tolerance Test | Ovariectomy | Osteoblasts - drug effects | Osteogenesis - drug effects | Bone Resorption - drug therapy | Bone Resorption - complications | Lumbar Vertebrae - drug effects | Mitochondria - metabolism | Genetic Markers | Mitochondria - drug effects | Rats, Sprague-Dawley | Up-Regulation - drug effects | Osteoblasts - pathology | Animals | Signal Transduction - drug effects | Cell Differentiation - drug effects | Mice, Inbred BALB C | Glucose metabolism | Osteoporosis | Parathyroid hormone | Leptin | Estrogen | Physiological aspects | Insulin resistance | Postmenopausal women | Body weight | Index Medicus
Journal Article
Journal of the American Medical Directors Association, ISSN 1525-8610, 2015, Volume 16, Issue 9, pp. 740 - 747
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2012, Volume 7, Issue 5, pp. e37563 - e37563
Background: Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC). Sarcopenia has been associated... 
TOMOGRAPHY | SKELETAL-MUSCLE | CANCER-PATIENTS | SOLID TUMORS | MULTIDISCIPLINARY SCIENCES | VALIDATION | BODY-COMPOSITION | INHIBITOR | PHASE-I | CARE | Niacinamide - analogs & derivatives | Humans | Middle Aged | Liver Neoplasms - drug therapy | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Dose-Response Relationship, Drug | Sarcopenia - chemically induced | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Liver Neoplasms - metabolism | Survival Analysis | Adult | Aged | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Carcinoma, Hepatocellular - metabolism | Pyridines - therapeutic use | Antimitotic agents | Medical research | Sarcopenia | Analysis | Diarrhea | Medicine, Experimental | Hepatoma | Antineoplastic agents | Liver cirrhosis | Nuclear magnetic resonance--NMR | Laboratories | Toxicity | Oncology | Hepatocellular carcinoma | Males | Body composition | Body mass index | Liver cancer | Angiogenesis | Toxicology | Computed tomography | Tomography | Nosocomial infections | Drug dosages | Teaching hospitals | Hypertension | Medical imaging | Pharmacology | Metabolism | Patients | Constraining | Feet | Musculoskeletal system | Clinical medicine | Pharmacokinetics | Cancer | Tumors | Index Medicus | Nuclear magnetic resonance | NMR
Journal Article
Journal Article
Experimental Gerontology, ISSN 0531-5565, 09/2013, Volume 48, Issue 9, pp. 973 - 984
Loss of myonuclei by apoptosis is thought to contribute to sarcopenia. We have previously shown, that the leucine metabolite, β-hydroxy-β-methylbutyrate (HMB)... 
Muscle hypertrophy | Sarcopenia | Muscle atrophy | Muscle function | Satellite cells | Nutrition | OXIDATIVE STRESS | REGULATORY FACTORS | BODY-COMPOSITION | OLD RATS | GERIATRICS & GERONTOLOGY | SKELETAL-MUSCLE | YOUNG | HINDLIMB SUSPENSION | RESISTANCE EXERCISE | GASTROCNEMIUS-MUSCLES | GROWTH | TOR Serine-Threonine Kinases - metabolism | Isometric Contraction - drug effects | Rats, Inbred F344 | Body Weight - drug effects | Male | Muscular Disorders, Atrophic - physiopathology | Stem Cells - metabolism | Valerates - pharmacology | Satellite Cells, Skeletal Muscle - pathology | Muscular Disorders, Atrophic - drug therapy | Valerates - therapeutic use | Muscle, Skeletal - drug effects | Muscular Disorders, Atrophic - pathology | Drug Evaluation, Preclinical | Rats | Nuclear Proteins - metabolism | MyoD Protein - metabolism | Hindlimb Suspension | Aging - pathology | Eating - drug effects | Satellite Cells, Skeletal Muscle - drug effects | Organ Size - drug effects | Animals | Aging - physiology | Signal Transduction - drug effects | Cell Differentiation - drug effects | Muscle, Skeletal - physiopathology | Stem Cells - drug effects | Stem Cells - pathology | Signal Transduction - physiology | Cell Proliferation - drug effects | Muscle, Skeletal - pathology | Dietary Supplements | Myogenin - metabolism | Paired Box Transcription Factors - metabolism | Aging - metabolism | Index Medicus
Journal Article